Abstract Library

#3043 Angiogenetic Markers as Prognostic Predictors in Neuroendocrine Neoplasms

Introduction: Neoangiogenesis is crucial for NEN development and metastatization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Puliani G

Authors: Puliani G, Feola T, Sesti F, Sciarra F, Campolo F,

Keywords: biomarkers, prognosis,

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,

#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Landoni L, Nessi C, Muffatti F,

Keywords: pancreatic neuroendocrine tumors, recurrence, surgery, locoregional treatment, systemic treatment,

#2806 Sarcopenia: Don't Judge a Book by It's Cover

Introduction: Sarcopenia is characterised by loss of muscle mass and function. We previously reported anthropometrical data for a range of NET diagnoses within 3 months of diagnosis. The majority of NET patients were overweight or obese, however reduced muscle function was observed in over half of patients regardless of BMI and other parameters.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Whyand T, Chotai de Lima Y, Caplin M,

Keywords: Neuroendocrine neoplasm, nutrition, dietitian, sarcopenia,

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,